IVIVR Assessing PK Parameters Used to Establish Bioequivalence

Inclusion Criteria: * Body mass index of 18.0 to 35.0 kg/m2 inclusive, or if outside the range, considered not clinically significant by the Investigator. Must not exceed 40.0 kg/m2. * Must agree to use an adequate method of contraception Exclusion Criteria: * Subjects who test positive for the HLA-B\*5801 allele. * Subjects who have received the last dose of an IMP (or treatment with a medical device) within the previous 3 months prior to Day 1 or is currently participating in another study of an IMP (or medical device). * History of any drug or alcohol abuse in the past 2 years. * Regular alcohol consumption in males \>21 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine). * Current smokers and those who have smoked within the last 12 months prior to Screening. A breath carbon monoxide reading of greater than 10 ppm at Screening. * Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the Investigator at Screening. * Clinically significant screening laboratory parameters (biochemistry \[AST or ALT \> 1.5 × ULN\], hematology or urinalysis) as judged by the Investigator (laboratory parameters are listed in Appendix 1). * Positive drugs of abuse test result during Screening or at Admission (drugs of abuse tests are listed in Appendix 1). * Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results. * Subjects with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. * History of cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease as judged by the Investigator. * Evidence of renal impairment at Screening, as indicated by an estimated creatinine clearance of \<90 mL/min using the Cockcroft-Gault equation. * Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients. * Presence or history of clinically significant allergy requiring treatment, as judged by the Investigator. Hayfever is allowed unless it is active. * Donation or loss of greater than 400 mL of blood within the previous 3 months prior to Screening. * Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other than up to 4 g per day paracetamol) or herbal remedies in the 14 days before IMP administration (See Section 11.4).